Evaluation and validation of p53 expression in oral cavity and laryngeal carcinomas and their precancerous lesions for the purpose of early tumor detection, as well as a predictor of treatment response and the occurrence of recurrence

Evaluation and validation of p53 expression in oral cavity and laryngeal carcinomas and their precancerous lesions for the purpose of early tumor detection, as well as a predictor of treatment response and the occurrence of recurrence - p53

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00040625

Enrollment

7200

Registered

2026-06-15

Start date

2026-06-02

Completion date

Unknown

Last updated

2026-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dysplasia, Carcinoma, and Leukoplakia in Head and Neck Tumors

Interventions

Group 1: A retrospective analysis of all patients with dysplasia, leukoplakia, and carcinoma in the head and neck region between 2010 and 2025.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with dysplasia, leukoplakia, or carcinoma in the head and neck region

Exclusion criteria

Exclusion criteria: Patients without dysplasia, leukoplakia, or carcinoma in the head and neck region

Design outcomes

Primary

Measure	Time frame
Evaluation and validation of p53 expression as a prognostic marker for the progression of dysplasia and for treatment response and follow-up in carcinomas	—

Countries

Germany

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Jun 29, 2026